Gradientech welcomes investment from commercial partner
The diagnostics company Gradientech today announces the collaboration with a.d.a. SRL as commercial partner for the Italian clinical microbiology market for its QuickMIC® system for rapid antibiotic susceptibility testing of positive blood cultures. Based on a strong believe in the diagnostic product, a.d.a. SRL has also decided to make an investment in Gradientech.
Following the CE-IVD registration of the QuickMIC® antibiotic susceptibility testing (AST) system during 2022, the commercialisation has started in selected European markets. Italy is one of the most important markets in Europe regarding AST of blood samples, driven by the high rate of antibiotic prescription and the emerging risk of antibiotic resistance.
“We are very honoured and enthusiastic about our commercial collaboration with Italian a.d.a SRL so far. Managed by the highly experienced Andrea Grillo and Pietro Lombardi a.d.a. is today one of the leading distributors in Italy of automated systems for the clinical microbiology market where they serve more than 200 laboratories”, says Sara Thorslund, CEO of Gradientech. “We for example recently joined a.d.a to exhibit the QuickMIC® system on the large AMCLI congress, where we experienced great interest in our newly launched system from the Italian market. I very much welcome a.d.a.’s recent decision to also join Gradientech as shareholders, from a financial perspective of course, but also as a proof of their strong believe in QuickMIC®.”
“Since the beginning of our cooperation with Gradientech we have been impressed by the company’s expertise in the AST area, heavily supporting their strong commitment to deliver the innovative fast technology of QuickMIC® to the market. The system provides precise MIC results in just 2 to 4 hours, thus concretely contributing to saving critical patients’ lives. The common view of our companies, and us strongly believing in promoting such an innovative diagnostic system to the clinical microbiology market, made us come to the obvious decision not only to start acting as Gradientech’s commercial partner in Italy, but also to join as shareholders”, says both Andrea Grillo, Managing Director and Pietro Lombardi, Scientific Director of a.d.a. SRL.
Following the financial investment, a.d.a. SRL becomes one of the ten largest shareholders of Gradientech.
For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC® allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
